Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Clinical Implications of Findings on Paclitaxel and Atezolizumab
Posted: Sunday, October 4, 2020
Lisa A. Carey, MD, of the University of North Carolina, compares the negative findings of IMpassion131 with other similar studies in a discussion of prescribing paclitaxel and atezolizumab for patients with locally advanced or metastatic triple-negative breast cancer.
